Suchergebnisse

Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity

Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions